Why Questcor Pharmaceuticals Inc. Soared Today

Why Questcor pharmaceuticals soared today.

Jan 16, 2014 at 4:37PM

Questcor Pharmaceuticals (NASDAQ:QCOR) is up over 10% today on unusually high volume following CEO Don Bailey's presentation at the 32nd annual J.P. Morgan Healthcare Conference. What started out as a fairly routine tour of the company's financials and lead commercial candidate, Acthar Gel, quickly turned into statements that suggest radical changes may be coming to Questcor.

From an investor's viewpoint, the most interesting part is that these statements came completely out of left field, leaving short sellers little room to find cover. In case you are new to this story, Questcor is quite a unique stock in the biotech sector. Despite growing revenues by double-digits over the last few quarters, short sellers have piled into the stock based upon ongoing investigations into the company's marketing practices for Acthar. As a result, Questcor shares have been trading for as little as three times annual sales lately. In the frothy biotech sector, that's basically unheard of.

Questcor's management, however, has actively fought back against short sellers by increasing dividends, instituting a hefty share buyback program, among other measures. Nonetheless, shorts have continued to attack the stock without mercy over the past year.

CEO mildly announces radical changes on the horizon
Mr. Bailey caught many investors off guard today by casually announcing during the company's presentation that Questcor is exploring the possibility of going private. If that wasn't enough, he later suggests that moving the company abroad might be a good idea to lessen the company's tax burden under U.S. Law. While these two bombshells started the rally, I believe what is most profound is Mr. Bailey's acknowledgement that it's time that Questcor moves beyond Acthar. 

What to do with all this cash?
There is no doubt that Questcor has been generating significant revenue from its highly successful orphan drug Acthar. Sales should top $1 billion year over year, once the company announces fourth quarter earnings next month. And so far, Questcor has primarily used this mountain of cash to buyback stock and reward shareholders by increasing dividends. In my view, however, the best way to quiet the critics about investigations into Acthar is to acquire or license another blockbuster drug. That appears to be an avenue Questcor is actively exploring this year.

Foolish final thoughts
With all of the licensing, partnering, and straight-up buyouts going on in the sector right now, Mr. Bailey's statements don't exactly surprise me. And with the company facing mounting criticism over Acthar's marketing, something big was bound to happen this year. Looking ahead, I personally think a merger with a company like Jazz Pharmaceuticals or Shire makes a lot of sense in terms of the synergies such a move would create. Regardless, Questcor definitely woke up the market today and looks ready to generate more debate among investors in 2014.

Two biotech stock picks to watch
The best way to play the biotech space is to find companies that shun the status quo and instead discover revolutionary, groundbreaking technologies. In the Motley Fool's brand-new FREE report "2 Game-Changing Biotechs Revolutionizing the Way We Treat Cancer," find out about a new technology that big pharma is endorsing through partnerships, and the two companies that are set to profit from this emerging drug class. Click here to get your copy today.

George Budwell has no position in any stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Money to your ears - A great FREE investing resource for you

The best way to get your regular dose of market and money insights is our suite of free podcasts ... what we like to think of as “binge-worthy finance.”

Feb 1, 2016 at 5:03PM

Whether we're in the midst of earnings season or riding out the market's lulls, you want to know the best strategies for your money.

And you'll want to go beyond the hype of screaming TV personalities, fear-mongering ads, and "analysis" from people who might have your email address ... but no track record of success.

In short, you want a voice of reason you can count on.

A 2015 Business Insider article titled, "11 websites to bookmark if you want to get rich," rated The Motley Fool as the #1 place online to get smarter about investing.

And one of the easiest, most enjoyable, most valuable ways to get your regular dose of market and money insights is our suite of free podcasts ... what we like to think of as "binge-worthy finance."

Whether you make it part of your daily commute or you save up and listen to a handful of episodes for your 50-mile bike rides or long soaks in a bubble bath (or both!), the podcasts make sense of your money.

And unlike so many who want to make the subjects of personal finance and investing complicated and scary, our podcasts are clear, insightful, and (yes, it's true) fun.

Our free suite of podcasts

Motley Fool Money features a team of our analysts discussing the week's top business and investing stories, interviews, and an inside look at the stocks on our radar. The show is also heard weekly on dozens of radio stations across the country.

The hosts of Motley Fool Answers challenge the conventional wisdom on life's biggest financial issues to reveal what you really need to know to make smart money moves.

David Gardner, co-founder of The Motley Fool, is among the most respected and trusted sources on investing. And he's the host of Rule Breaker Investing, in which he shares his insights into today's most innovative and disruptive companies ... and how to profit from them.

Market Foolery is our daily look at stocks in the news, as well as the top business and investing stories.

And Industry Focus offers a deeper dive into a specific industry and the stories making headlines. Healthcare, technology, energy, consumer goods, and other industries take turns in the spotlight.

They're all informative, entertaining, and eminently listenable. Rule Breaker Investing and Answers are timeless, so it's worth going back to and listening from the very start; the other three are focused more on today's events, so listen to the most recent first.

All are available for free at www.fool.com/podcasts.

If you're looking for a friendly voice ... with great advice on how to make the most of your money ... from a business with a lengthy track record of success ... in clear, compelling language ... I encourage you to give a listen to our free podcasts.

Head to www.fool.com/podcasts, give them a spin, and you can subscribe there (at iTunes, Stitcher, or our other partners) if you want to receive them regularly.

It's money to your ears.


Compare Brokers